Join the Oncology Voice Network. Join for Free
Season 1, Episode 9: Career Insights From a CEO with Mark Erlander

Season 1, Episode 9: Career Insights From a CEO with Mark Erlander


Share This Article


We are thrilled to welcome Mark Erlander PHD, CEO of Cardiff Oncology, shares his journey from a PhD in neuroscience to leading an oncology company. He discusses the calculated risks he took throughout his career and the importance of following your passion. Erlander emphasizes the need for leaders to be motivated and to create a team that is excited to work together. "Create a motivated team by fostering trust, respect, and providing resources" He tells up and comers to do something they are truly excited about, but also be be opportunistic and willing to take calculated risks. We jump in to discussions on the future of cancer treatments, including targeted therapies and personalized medicine.

Key Points:

❇Follow your passion and do something you are truly excited about

🤗Create a motivated team by fostering trust, respect, and providing resources

📈Be opportunistic and willing to take calculated risks

❌Never settle for something that is less than what you want to achieve

💊The future of cancer treatments includes targeted therapies and personalized medicine 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN